论文部分内容阅读
三苯氧胺用于乳癌的辅助治疗历时已近20年。尽管它的治愈乳癌及提高总体生存方面的优点已被证实,但仍存在有关本疗法的最合理的用药持续时间以及配合化疗的协同疗效等问题。本文旨在研究对于有淋巴结转移的乳癌病人行改良乳腺切除术后应用化疗加内分泌治疗的效果。方法:选择311例腋下淋巴结转移的乳癌病人,年龄均小于76岁,全部行改良乳腺切除术。切下的肿瘤测定雌激素受体(ER),<3 fmol/mg肿瘤细胞蛋白为阴性,≥3 fmol/mg为阳性。切除标本送病理检查。病人随机分在三个治疗组内。治疗组包括CMF组(环磷酰胺,氨甲嘌呤,5-Fu),CMF加三苯氧胺组,CMF加三苯氧胺和卡介苗组。用法为环磷酰胺12个月中每月1～14号给药,每次60 mg/m~3,分二顿口
Tamoxifen has been used for the adjuvant treatment of breast cancer for nearly 20 years. Although its advantages in curing breast cancer and improving overall survival have been confirmed, there are still issues related to the most reasonable duration of medication and the synergistic effect of chemotherapy. This article aims to investigate the effect of chemotherapy and endocrine therapy after modified mastectomy for breast cancer patients with lymph node metastases. METHODS: A total of 311 cases of breast cancer patients with axillary lymph node metastases were selected, all of whom were younger than 76 years old and all underwent modified mastectomy. The excised tumors were assayed for estrogen receptor (ER), < 3 fmol/mg tumor cell protein was negative, and ≥ 3 fmol/mg was positive. Resection specimens for pathological examination. The patients were randomly assigned to three treatment groups. The treatment group included CMF group (cyclophosphamide, methotrexate, 5-Fu), CMF plus tamoxifen group, CMF plus tamoxifen and BCG group. The use of cyclophosphamide is administered on the 1st to the 14th of each month for 12 months, 60 mg/m~3 each time.